Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8%

Loss narrows modestly. Dyne Therapeutics reported a loss of $0.76 per share for Q4 2025.  The biotech posted a narrower loss than expected by 4.4%, marking sequential improvement from the prior quarter’s $0.76 loss. Shares surged 11.8% to $19.78 on volume of 5.6 million, suggesting investors view the narrowing trajectory favorably despite the pre-revenue stage.

No revenue yet. The company reported zero revenue for the quarter, consistent with its clinical-stage profile. Operating loss totaled $116.1 million, driven primarily by $95.4 million in research and development expenses as the company advances its pipeline. The net loss of $112 million reflects ongoing investment in drug development programs. Operating cash flow was negative $111.8 million, with free cash flow at negative $112.3 million after $484,000 in capital expenditures.